Does tremfya cause weight gain as a side effect?

Does Tremfya cause weight gain?

Clinical trial data and post-marketing reports do not list weight gain as a common side effect of Tremfya (guselkumab). Most patients do not report changes in weight while taking the drug.

What do the prescribing information and trials show?

The FDA-approved label lists upper respiratory infections, headache, injection-site reactions, and joint pain as frequent adverse events. Weight gain does not appear in these sections or in the summary of safety findings from the pivotal psoriasis and psoriatic arthritis studies.

Why do some patients report weight gain anyway?

Individual factors such as reduced inflammation, changes in activity level, or concurrent medications (for example, corticosteroids) can lead to weight changes that patients may attribute to Tremfya. These reports remain anecdotal and are not confirmed in controlled data.

Are there differences between Tremfya and other IL-23 inhibitors?

Comparative studies have not identified meaningful differences in weight-related outcomes among guselkumab, risankizumab, and tildrakizumab. All three agents show similar safety profiles in this regard.

When should a patient contact their doctor about weight changes?

Rapid or unexplained weight gain, swelling, or new shortness of breath warrants medical evaluation. These symptoms could signal fluid retention or another condition unrelated to Tremfya.

How is Tremfya monitored for long-term safety?

Post-approval registries and pharmacovigilance programs continue to track all reported events, including any unexpected weight changes. No new signals have prompted label updates for weight gain to date.

Sources
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761061s009lbl.pdf